Researchers of Radboudumc have discovered that the iron in metal surgical implants can activate drugs such as antibiotics, thus enabling targeted therapy. With this method, antibiotics in the blood can target infections in the vicinity of an implant, write researchers Marja Bulte-ter Meer and Leo Schultze Kool in Chemical Communications.Metal implants are widely used in medical care, from artificial heart valves to trauma surgery and from dental prostheses to orthopedic surgery. However, the introduction of artificial tissue in the body entails a high risk of bacterial infection. As a result, patients with an implant often are required to use preventative antibiotics for long periods. This does not always have the desired effect, and can even be harmful, because these antibiotics are active throughout the body.
It is therefore more effective if drugs are active only in the vicinity of the implant, for example by administering the drug locally. One method to achieve this is known as enzyme-prodrug therapy (EPT). Patients receive inactive drugs – prodrugs – which can be converted into active drugs in the body. But for this work, the implant has to contain the enzymes needed for this conversion.
Discovered by accident
Marja Bulte-ter Meer, a PhD candidate working with Professor of Interventional Radiology Leo Schultze Kool of Radboudumc, discovered by accident that a certain type of widely used metal implant has an enzyme-like effect. This enables the implants to cleave sugar groups from molecules. This mechanism can be used for drug treatment by adding a sugar group to a drug, which results in a prodrug. As soon as the sugar group is cleaved from the molecule, the drug becomes active.
The researchers made their discovery when working with implants consisting of an alloy of cobalt, nickel, chromium and molybdenum. The implants themselves were inert, but a version with small grooves in the metal had strong activity in cleaving sugar groups. On closer inspection it appeared that iron had been deposited in these grooves. This iron turned out to be responsible for the efficient conversion of the drugs to their active form. The underlying mechanism for this process is not yet known.
Implants of pure iron would work best with enzyme-prodrug therapy. However, pure iron is chemically instable and cannot be used to make implants. The researchers therefore thought it would be a better idea to provide existing implants with an iron coating. Laboratory tests have shown that various implant materials with an iron coating can effectively convert an antibiotic pro-drug to an active drug.
During the past 18 months, Bulte-ter Meer and Schulze Kool have developed their discovery in collaboration with Aarhus University (Denmark) and implant manufacturer Fort Wayne Medical. The researchers have now applied for a patent on the enzymatic function of metallic implants. As a result, this technique can be used extensively for a wide range of drugs.
Marja Bulte - ter Meer is member of theme Rare cancers.
Leo Schultze Kool is member of theme Vascular damage.
Related news items
How do we keep new technology affordable to improve the lives of people?16 May 2019
Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.read more
Dutch Kidney Foundation Innovation grant for Tom Nijenhuis14 May 2019
Tom Nijenhuis, theme Renal disorders, received this grant for his research project “Salt supplementation in Gitelman syndrome: A simple intervention using an innovative N-of-1 trial approach”.read more
Algorithm calculates the presence and aggressiveness of prostate tumors14 May 2019
A computer program that analyzes MRI images can reliably map the presence and even the aggressiveness of a prostate tumor. This is what Radboudumc researchers and international colleagues have published in the scientific journal Investigative Radiology.read more
Universal tumor BRCA1/2 testing of ovarian cancer13 May 2019
Marjolijn Ligtenberg, Janet Vos and Nicoline Hoogerbrugge, assessed the feasibility of a workflow for universal tumor DNA BRCA1/2 testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition testing. They have published their findings in the JNCI.read more